Sangamo (SGMO) development chief sells 345,942 shares at $0.26

Rhea-AI Filing Summary

Sangamo Therapeutics SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported an open-market sale of Common Stock. She sold 345,942 shares on April 21, 2026 at a weighted-average price of $0.2578 per share in multiple trades ranging from $0.2533 to $0.2634.

Following this transaction, she directly holds 332,769 shares of Sangamo Therapeutics Common Stock. The filing does not report any derivative security exercises, indicating this was a straightforward share sale rather than an option-related transaction.

Insider Trade Summary

Net Seller: 345,942 shares ($89,184)

Net Sell 1 txn

Insider Dubois-Stringfellow Nathalie

Role SVP-CHIEF DEVELOPMENT OFFICER

Sold 345,942 shs ($89K)

Type	Security	Shares	Price	Value
Sale	Common Stock	345,942	$0.2578	$89K

Holdings After Transaction: Common Stock — 332,769 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 345,942 shares Weighted-average sale price: $0.2578 per share Price range: $0.2533–$0.2634 per share +2 more

5 metrics

Shares sold 345,942 shares Open-market sale on April 21, 2026

Weighted-average sale price $0.2578 per share Common Stock sale

Price range $0.2533–$0.2634 per share Individual trade prices within the sale

Shares held after transaction 332,769 shares Direct ownership post-sale

Net shares sold 345,942 shares Net-sell direction in transaction summary

Key Terms

open-market sale, Common Stock, weighted-average price, Securities and Exchange Commission, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

weighted-average price financial

"The price reported is a weighted-average price."

Securities and Exchange Commission regulatory

"provide upon request to the staff of the Securities and Exchange Commission"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dubois-Stringfellow Nathalie

(Last) (First) (Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND CALIFORNIA 94804

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP-CHIEF DEVELOPMENT OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/21/2026		S		345,942	D	$0.2578(1)	332,769	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2634, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ Scott Willoughby, Attorney-in-Fact	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SGMO report for Nathalie Dubois-Stringfellow?

Sangamo Therapeutics (SGMO) reported that SVP-Chief Development Officer Nathalie Dubois-Stringfellow sold 345,942 shares of Common Stock. The sale occurred on April 21, 2026, as an open-market transaction disclosed in a Form 4 filing with regulators.

How many SGMO shares did Nathalie Dubois-Stringfellow sell and at what price?

She sold 345,942 Sangamo Therapeutics (SGMO) Common Stock shares at a weighted-average price of $0.2578. The footnote states these shares were sold in multiple trades, with prices ranging from $0.2533 to $0.2634 per share.

How many SGMO shares does Nathalie Dubois-Stringfellow hold after the sale?

After the reported sale, Nathalie Dubois-Stringfellow directly holds 332,769 shares of Sangamo Therapeutics (SGMO) Common Stock. This post-transaction balance is explicitly stated in the Form 4 as the total shares following the open-market sale.

Was the SGMO insider sale by Nathalie Dubois-Stringfellow an open-market transaction?

Yes. The Form 4 identifies the transaction code as “S” and describes it as an open-market sale. The weighted-average sale price was $0.2578, based on multiple trades between $0.2533 and $0.2634 per share on April 21, 2026.

Does Nathalie Dubois-Stringfellow’s SGMO filing involve any derivatives or options?

No derivative transactions are reported in this Form 4 for Sangamo Therapeutics (SGMO). The filing lists only a non-derivative Common Stock sale and shows an empty derivative summary, indicating no option exercises or other derivative activity in this report.